We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+8.08%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.07B
AUM Growth
+$64.2M
Cap. Flow
+$82M
Cap. Flow %
7.68%
Top 10 Hldgs %
64.05%
Holding
53
New
4
Increased
9
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$22.6M
2
MDCO
Medicines Co
MDCO
+$21.8M
3
INSM icon
Insmed
INSM
+$16.1M
4
CHMA
Chiasma, Inc. Common Stock
CHMA
+$15.6M
5
ZYME icon
Zymeworks
ZYME
+$15.3M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$26M
2
ACER
Acer Therapeutics Inc
ACER
+$14.1M
3
QURE icon
uniQure
QURE
+$10.8M
4
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.55M
5
ZLAB icon
Zai Lab
ZLAB
+$2.11M

Sector Composition

Rank Sector Weight
1 Healthcare 94.71%
2 Materials 2.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACER
51
DELISTED
Acer Therapeutics Inc
ACER
– –
-579,051
Closed -$14.1M
SBBP
52
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-914,062
Closed -$4.55M
BHVN
53
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-504,980
Closed -$26M
1 2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Vivo Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Vivo Capital held 53 positions worth $1.07B, up 6.4% from $1B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Vivo Capital deployed $82M of net new capital in Q2 2019, opening 4 new positions and adding to 9 existing holdings. Its largest new stake was Medicines Co: 669,012 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Genocea Biosciences, Inc., an estimated $1.83M trimmed.

  • Vivo Capital's largest Q2 2019 buy was Medicines Co: 669,012 shares worth $24.4M.
  • Vivo Capital added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $22.6M increase.
  • Vivo Capital's biggest Q2 2019 reduction was Genocea Biosciences, Inc., cutting an estimated $1.83M.
  • Vivo Capital fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019, selling an estimated $26M.
  • Vivo Capital's ten largest holdings make up 64% of its $1.07B portfolio in Q2 2019.
  • Vivo Capital opened 4 new positions and closed 7 in Q2 2019.
  • Vivo Capital's portfolio value rose 6.4% quarter-over-quarter to $1.07B.

Based on Vivo Capital's 13F filing for Q2 2019, filed 13 Aug 2019.